IN THE UNITED STATES PATENT AND TRADEMARK OFFICE MAY 2006

Applicants:

Philippe G. Nantermet et al.

Serial No.:

To Be Assigned

Case No.: 21585YP

US Nat'l Filing Date:

May 10, 2006

Int'l Appl'n No.

PCT/US2004/038927

Int'l Filing Date:

19 November 2004

For:

BENZYLETHER AND BENZYLAMINO BETA-SECRETASE

INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S

DISEASE

MAIL STOP PCT Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT EXPRESS MAIL NO.

EXPRESS MAIL NO. EL991585 288 U.S.

I hereby certify that this correspondence is being deposited

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450

MAILED BY DATE

100 UL

Case No .: 21585YP Page

This Information Disclosure State 1990 18 10 to a radiant publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Reference A on the accompanying PTO 1440 form was cited in the International Search Report for this application. A copy of the International Search Report is enclosed with this Information Disclosure Statement.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

ohn C. Todaro, Reg. No. 36,036 ttorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-0125

Date: May 10, 2006

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicate Patent and Trademark Office, U.S DEPARTMENT OF COMMERCE

. 1				Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE			
Substitute for form 1449A/PTO				COMPLETE IF KNOWN			
I	NFORMATION 1	DIS	CLOSURE	Application Number	To Be Assigned TO 1 2 NAY 2006		
	TATEMENT BY	A TO	DIICANT	Filing Date	May 10, 2006		
٥	IAIEMENI DI	AP	PLICANI	First Named Inventor	Philippe de Namtermer		
	(,	Group Art Unit	To Be Assigned		
	(use as many sheets	as n	ecessary)	Examiner Name	To Be Assigned		
Sheet	1	of	2	Attorney Docket Number	21585YP		
							

		-	U.S. PA	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Α	6,812,346		Dube et al.	11/02/2004
			_		

			FOREI	GN PATENT	T DOCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document Office Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	В	PCT	WO 2004/043916		Merck & Co., Inc.	05/27/2004	
	С	PCT	WO 2005/004802		Merck & Co., Inc.	01/20/2005	
	D PCT E PCT		WO 2005/004803		Merck & Co., Inc.	01/20/2005	
			WO 2005/032471		Merck & Co., Inc.	04/14/2005	
	F	PCT	WO 2003/106405		Sunesis Pharmaceuticals, Inc.	12/24/2003	
	G PCT		WO 2005/005374		Sunesis Pharmaceuticals, Inc.	01/20/2005	

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use 131/2006. OMB 0651-00 Approved for use 131/2006. OMB 0651-00 Approved for use 131/2006. OMB 0651-00 Page 1 and Use 141/2009. Office: Approved for use 131/2006. OMB 0651-00 Approved for use 131/200
--

Su	Substitute for form 1449B/PTO		COMPLETE IF KNOWN			
	NFORMATION 1	DIS	CLOSURE	Application Number	To Be Assigned / 578 953	
8	TATEMENT DV	AT	DI ICANT	Filing Date	May 10, 2006	
3	STATEMENT BY APPLICANT			First Named Inventor	Philippe G. Nantermet	
	<i>C</i> 1		,	Group Art Unit	To Be Assigned	
	(use as many sheets	as n	necessary)	Examiner Name	To Be Assigned	
Sheet	2	of	2	Attorney Docket Number	21585YP	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
	Н	Coburn et al., "Identification of a Small Molecule Nonpeptide," J. Med. Chem., Vol. 47, pp. 6117-6119 (2004)				
		· ·				

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., -7/12/2005)